Karyopharm Therapeutics Announces Board Changes and New CMO
Ticker: KPTI · Form: 8-K · Filed: May 31, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-composition, filing
TL;DR
Karyopharm shakes up the board, appoints new CMO, and files financials.
AI Summary
Karyopharm Therapeutics Inc. announced on May 29, 2024, a series of corporate actions including the departure of Director Michael W. Yothers, the election of new Directors Dr. Jonathan M. Kay and Dr. David M. Roth, and the appointment of Dr. Jonathan M. Kay as Chief Medical Officer. The company also reported on matters submitted to a vote of security holders and filed financial statements and exhibits.
Why It Matters
Changes in board composition and executive leadership can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Board and executive changes, coupled with routine financial filings, introduce a moderate level of uncertainty regarding future strategic direction and operational execution.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- Michael W. Yothers (person) — Departing Director
- Dr. Jonathan M. Kay (person) — Elected Director and Appointed Chief Medical Officer
- Dr. David M. Roth (person) — Elected Director
- May 29, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan M. Kay has been appointed as the new Chief Medical Officer.
Who has departed from the Board of Directors?
Michael W. Yothers has departed from the Board of Directors.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 29, 2024.
What are the principal executive offices of Karyopharm Therapeutics Inc.?
The principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts, 02459.
What other items are reported in this 8-K filing besides director and officer changes?
This 8-K filing also reports on the election of directors, compensatory arrangements of certain officers, submission of matters to a vote of security holders, and financial statements and exhibits.
Filing Stats: 1,123 words · 4 min read · ~4 pages · Grade level 10.8 · Accepted 2024-05-31 08:00:30
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
Filing Documents
- d827879d8k.htm (8-K) — 44KB
- 0001193125-24-151049.txt ( ) — 165KB
- kpti-20240529.xsd (EX-101.SCH) — 3KB
- kpti-20240529_lab.xml (EX-101.LAB) — 18KB
- kpti-20240529_pre.xml (EX-101.PRE) — 11KB
- d827879d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: May 31, 2024 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary